Stockreport

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD)...

Pasithea Therapeutics Corp.  (KTTA) 
PDF -- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-pro [Read more]